Delcath Systems, Inc, a leading developer of regional therapy for cancer, announced today that its management will present at the Maxim Group Growth Conference in New York City on Tuesday, October 7, 2008. The conference will be held at the Grand Hyatt New York Hotel. The Maxim Group Growth Conference will feature interactive presentations from over 80 companies, as well as one-on-one meetings with executives from the Healthcare, Technology, Shipping/Transportation and Emerging Growth Sectors. Attendees will include securities analysts, fund managers and institutional investors
About Delcath Systems, Inc.
Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company has developed a proprietary, patented system which will improve the efficacy of cancer treatment while reducing the considerable, systemic side-effects of chemotherapy. Delcath's novel drug delivery platform is capable of delivering anti-cancer drugs at very high doses to a specific organ or region of the body while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.
About Maxim Group
Maxim Group is a full-service investment banking, securities and investment management firm headquartered in New York. The Firm provides an array of financial services including: investment banking, equity research, private wealth management, structured products, and global institutional equity, fixed-income and derivative sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
Contact:
Company Contact:
Delcath Systems, Inc.
Richard Taney
(212) 489-2100
Email Contact
Investor Relations Contact:
Strategic Growth International, Inc.
Richard E. Cooper/Cass Almendral
(212) 838-1444
Email Contact
Email Contact
Public Relations Contact:
Rubenstein Associates, Inc.
Robin Wagge
(212) 843-8006
Email Contact
Source: Delcath Systems, Inc.
About Delcath Systems, Inc.
Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company has developed a proprietary, patented system which will improve the efficacy of cancer treatment while reducing the considerable, systemic side-effects of chemotherapy. Delcath's novel drug delivery platform is capable of delivering anti-cancer drugs at very high doses to a specific organ or region of the body while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.
About Maxim Group
Maxim Group is a full-service investment banking, securities and investment management firm headquartered in New York. The Firm provides an array of financial services including: investment banking, equity research, private wealth management, structured products, and global institutional equity, fixed-income and derivative sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
Contact:
Company Contact:
Delcath Systems, Inc.
Richard Taney
(212) 489-2100
Email Contact
Investor Relations Contact:
Strategic Growth International, Inc.
Richard E. Cooper/Cass Almendral
(212) 838-1444
Email Contact
Email Contact
Public Relations Contact:
Rubenstein Associates, Inc.
Robin Wagge
(212) 843-8006
Email Contact
Source: Delcath Systems, Inc.
0 comments:
Post a Comment